Patent 11053215 was granted and assigned to Incyte on July, 2021 by the United States Patent and Trademark Office.
The present application is concerned with heterocyclic compounds that inhibit the activity of Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancers and other diseases.